Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 4

1(14.3%)

Phase 1

1(14.3%)

N/A

1(14.3%)

7Total

Phase 2(4)

Phase 4(1)

Phase 1(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06578507Phase 2Recruiting

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Role: lead

NCT03806452Phase 2Completed

SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

Role: lead

NCT04707235Active Not Recruiting

ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study

Role: lead

NCT03032055Unknown

Validation of a Predictive Score of Acute Chest Syndrome

Role: collaborator

NCT05470270Phase 2Completed

Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.

Role: lead

NCT02522104Phase 4Completed

Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)

Role: lead

NCT05025072Phase 1Completed

A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers

Role: lead

NCT02516579Completed

European Sickle Cell Disease Cohort - Hydroxyurea

Role: lead

NCT02721472Not ApplicableCompleted

Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease

Role: lead

NCT02957760Phase 2Unknown

Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.

Role: collaborator

All 10 trials loaded